K140215

# Co-Innovation Biotech Co.,Ltd.

# Section 5 - 510(k) Summary

Date of Summary Preparation: 5/19/2014

# 1. Submitter's Identifications

Submitter: Co-lnnovation Biotech Co.,Ltd.   
Address: No.13, Yanyuan Road, Tianhe District, Guangzhou, P.R. China Contact Person: Hong Feng   
Contact Email Address: fenghongfda@126.com   
Telephone: $\mathbf { + 8 6 }$ -20-62867285   
Fax: + 86 -20-62867285

2. Correspondent's Identifications

Correspondent's Name: Co-Innovation Biotech Co.,Ltd.   
Address: No. 13, Yanyuan Road, Tianhe District, Guangzhou, P.R. China Contact Person: Hong Feng   
Contact Email Address: fenghongfda@126.com   
Telephone: $\mathbf { \varepsilon } + { \mathbf { 8 6 } }$ -20-62867285   
Fax: + 86 -20-62867285

# 3. Name of the Device

Recommended classification regulation:

21 CFR 862.3150 Barbiturate test system   
21 CFR 862.3170 Benzodiazepine test system   
21 CFR 862.3610 Methamphetamine test system   
21 CFR 862.3620 Methadone test system   
21 CFR 862.3650 Opiate test system   
Unclassified,Enzyme immunoassay,phencyclidine

Device class: Class II   
Panel: Toxicology (91)   
Product code: DIS,JXM,DJC,DJR,DJGLCM

Common Name:

Barbiturates (BAR) Test System   
Benzodiazepines (BZO) Test System   
Methylenedioxymethamphetamine (MDMA) Test System   
Methadone (MTD) Test System   
Oxycodone (OXY) Test System   
Phencyclidine (PCP) Test System

# Proprietary names:

One Step Single/Multi-drug Test Cup One Step Single/Multi-drug Test Dipcard

# Co-Innovation Biotech Co.,Ltd.

# 4 The Predicate Devices

# K091588 UCP HomeT Drug Screening Test Cards UCP Home™M Drug Screening Test Cup

# 5 Device Description

One Step Single/Multi-drug Test Cup and One Step Single/Multi-drug Test Dipcard are competitive binding, lateral flow immunochromatographic assays for qualitatively the detection of Barbiturates, Benzodiazepines, Methylenedioxymethamphetamine, Methadone,Oxycodone, Phencyclidine and their metabolites at or above the cut-off levels as indicated. The tests can be performed without the use of an instrument.

# 6. Intended Use of Device

One Step Single/Multi-drug Test Cup and One Step Single/Multi-drug Test Dipcard are lateral flow chromatographic immunoassay designed to qualitatively detect the presence of drugs and drug metabolites in human urine at the following cut-off concentrations:

<table><tr><td rowspan=1 colspan=1>Test</td><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Cut-off level</td></tr><tr><td rowspan=1 colspan=1>Barbiturates (BAR)</td><td rowspan=1 colspan=1>Secobarbital</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Benzodiazepines (BZO)</td><td rowspan=1 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Methylenedioxymethamphetamine (MDMA)</td><td rowspan=1 colspan=1>3,4-Methylenedioxymethamphetamine</td><td rowspan=1 colspan=1>500 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Methadone (MTD)</td><td rowspan=1 colspan=1>Methadone</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Oxycodone (OXY)</td><td rowspan=1 colspan=1>Oxycodone</td><td rowspan=1 colspan=1>100 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Phencyclidine (PCP)</td><td rowspan=1 colspan=1>Phencyclidine</td><td rowspan=1 colspan=1>25 ng/mL</td></tr></table>

The tests contain two formats:1) Test Cup, 2) Test Dipcard, The test configuration comes with single drug screening test or any combinations of multiple drug screening tests. The test is intended for in vitro diagnostics use. They are intended for prescription use in clinical laboratories only and not for point-of-care use.

This assay provides only a preliminary analytical test result. Gas Chromatography/Mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

# 7. Comparison to Predicate Devices:

A summary comparison f eatures of the One Step Single/Multi-drug Test Cup and One Step

# Co-Innovation Biotech Co.,Ltd.

Single/Multi-drug Test Dipcard and the predicate devices is provided in the following Table:

<table><tr><td rowspan=1 colspan=1>Item            :</td><td rowspan=1 colspan=1>Device                            t</td><td rowspan=1 colspan=1>Predicate (K091588</td></tr><tr><td rowspan=1 colspan=1>Indication for use</td><td rowspan=1 colspan=1>Qualitative detection ofdrugs-of-abuse in urine ( Barbiturates,Benzodiazepines,Methylenedioxymethamphetamine,Methadone,Oxycodone,Phencyclidine)</td><td rowspan=1 colspan=1>Same (but the number ofdrugs detected different)</td></tr><tr><td rowspan=1 colspan=1>Intended Users</td><td rowspan=1 colspan=1>Prescription Use</td><td rowspan=1 colspan=1>Over the Counter (OTC) Useand Prescription Use</td></tr><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>Barbiturates:300 ng/mLBenzodiazepines:300 ng/mLMethylenedioxymethamphetamine:500ng/mLMethadone:300 ng/mLOxycodone:100 ng/mLPhencyclidine:25 ng/mL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Read time</td><td rowspan=1 colspan=1>5 minutes</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>4~30</td><td rowspan=1 colspan=1>2~30 </td></tr><tr><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Competitive binding, Lateral flowimmunochromatographic assay basedon the principle of antigen antibodyimmunochemistry</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Configuration</td><td rowspan=1 colspan=1>Dipcard and Cup</td><td rowspan=1 colspan=1>Card and Cup</td></tr></table>

# Remark:

1The subject devices have all features of the predicate device except the number of drugs detected and storage temperature condition . These differences do not affect the performance characteristics of the subject devices.

# 8. Performance Data:

# Accuracy

Single drug Test:

80 clinical urine specimens for each drug were analyzed by GC/MS and by one lot of the corresponding One Step Single drug Test Cup. Samples were divided by concentration into five categories:drug ree, less than half the cutoff, near cutoff negative, near cutoff positive, and high positive. Results were as follows:

<table><tr><td>Drug Test</td><td>Co-Innov ation Result</td><td>Drug free by GC/MS analysis</td><td>Less than half the cutoff concentration by GC/MS analysis</td><td>Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration)</td><td>Near Cutoff Positive (Between the cutoff and 50% above the cutoff</td><td>High Positive (greater than 50% above the cutoff concentration)</td><td>Total</td></tr><tr><td>BAR</td><td>+ 1</td><td>0</td><td>0</td><td>0</td><td>concentration) 6</td><td>34</td><td>80</td></tr></table>

# Co-Innovation Biotech Co.,Ltd.

Analysis of Discordant Results with One Step Single drug Test Cup   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>BZO</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>33</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>MDMA</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>34</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>MTD</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>S</td><td rowspan=1 colspan=1>35</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>OXY</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>34</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>PCP</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>35</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

<table><tr><td rowspan=1 colspan=3>One Step Single drug Test Cup</td><td rowspan=1 colspan=2>GC/MSAnalysis</td></tr><tr><td rowspan=1 colspan=1>Drug Test</td><td rowspan=1 colspan=1>Cutoff(ng/mL)</td><td rowspan=1 colspan=1>Test Result</td><td rowspan=1 colspan=1>DrugConcentration(ng/ml)</td><td rowspan=1 colspan=1>Drug in Urine</td></tr><tr><td rowspan=1 colspan=1>BZO</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>188:</td><td rowspan=1 colspan=1>Oxazepam</td></tr><tr><td rowspan=1 colspan=1>MDMA</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>715</td><td rowspan=1 colspan=1>3.4-Methylenedioxymethamphetamine</td></tr><tr><td rowspan=1 colspan=1>MTD</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>209</td><td rowspan=1 colspan=1>Methadone</td></tr><tr><td rowspan=1 colspan=1>PCP</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>Phencyclidine</td></tr></table>

80 clinical urine specimens for each drug were analyzed by GC/MS and by one lot of the corresponding One Step Single drug Test Dipcard. Samples were divided by concentration into v catere:drugee,ess than hal the uto nea uoff neativ, near cutof positiv, and high positive. Results were as follows:

Analysis of Discordant Results with One Step Single drug Test Dipcard   

<table><tr><td rowspan=1 colspan=1>DrugTest</td><td rowspan=1 colspan=1>Co-InnovationResult</td><td rowspan=1 colspan=1>Drug ree byGC/MS analysis</td><td rowspan=1 colspan=1>Less than halfthe cutoffconcentrationby GC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative (Between50% below thecutoff and the cutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive (Betweenthe cutoff and50% above thecutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(greater than50% above thecutoffconcentration)</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>BAR</td><td rowspan=1 colspan=1>÷</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>34</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>BZO</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>33</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>MDMA</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>34</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>MTD</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>35</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>OXY</td><td rowspan=1 colspan=1>\$</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>34</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>PCP</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>35</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

<table><tr><td rowspan=1 colspan=3>One Step Single drug Test Dipcard</td><td rowspan=1 colspan=2>GC/MSAnalysis</td></tr><tr><td rowspan=1 colspan=1>Drug Test</td><td rowspan=1 colspan=1>Cutoff(ng/mL)</td><td rowspan=1 colspan=1>Test Result</td><td rowspan=1 colspan=1>DrugConcentration(ng/mL)</td><td rowspan=1 colspan=1>Drug in Urine</td></tr><tr><td rowspan=1 colspan=1>BZO</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>Oxazepam  .</td></tr><tr><td rowspan=1 colspan=1>MDMA</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>715</td><td rowspan=1 colspan=1>3.4-Methylenedioxymethamphetamine</td></tr><tr><td rowspan=1 colspan=1>MTD</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>209</td><td rowspan=1 colspan=1>Methadone</td></tr></table>

# Co-Innovation Biotech Co.,Ltd.

<table><tr><td>PCP</td><td>25</td><td>Positive</td><td>23</td><td>Phencyclidine</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr></table>

Multi-drug Test:

80 clinical urine specimens for each drug were analyzed by GC/MS and by one lot of the corresponding One Step Multi-drug Test Cup. Samples were divided by concentration into five categories:drug free, less than half the cutoff, near cutoff negative, near cutoff positive, and high positive. Results were as follows:

Analysis ofDiscordant Results with One Step Multi-drug Test Cup   

<table><tr><td rowspan=1 colspan=1>DrugTest</td><td rowspan=1 colspan=1>Co-InnovationResult</td><td rowspan=1 colspan=1>Drug free byGC/MS analysis</td><td rowspan=1 colspan=1>Less than halfthe cutoffconcentrationby GC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative (Between50% below thecutoff and the cutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive (Betweenthe cutoff and50% above thecutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(greater than50% above thecutoffconcentration)</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>BAR</td><td rowspan=1 colspan=1>$\r}$</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>34</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>BZO</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>33</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>MDMA</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>34</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>S</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>MTD</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>35</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>OXY</td><td rowspan=1 colspan=1>$\ra}$</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>34</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>PCP</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>35</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

<table><tr><td rowspan=1 colspan=3>One Step Multi-drug Test Cup</td><td rowspan=1 colspan=2>GC/MS Analysis</td></tr><tr><td rowspan=1 colspan=1>Drug Test</td><td rowspan=1 colspan=1>Cutoff(ng/mL)</td><td rowspan=1 colspan=1>Test Result</td><td rowspan=1 colspan=1>DrugConcentration(ng/mL)</td><td rowspan=1 colspan=1>Drug in Urine</td></tr><tr><td rowspan=1 colspan=1>BZO</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>Oxazepam</td></tr><tr><td rowspan=1 colspan=1>MDMA</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>715</td><td rowspan=1 colspan=1>3,4-Methylenedioxymethamphetamine</td></tr><tr><td rowspan=1 colspan=1>MTD</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>209</td><td rowspan=1 colspan=1>Methadone</td></tr><tr><td rowspan=1 colspan=1>PCP</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>Phencyclidine</td></tr></table>

80 clinical urine specimens for each drug were analyzed by GC/MS and by one lot of the corresponding One Step Multi-drug Test Dipcard. Samples were divided by concentration into five categories drugfree,les than hal the cutoff, near cutoff negativ, near cutoff positive, and high positive. Results were as follows:

<table><tr><td rowspan=1 colspan=1>DrugTest</td><td rowspan=1 colspan=1>Co-InnovationResult</td><td rowspan=1 colspan=1>Drug free byGC/MS analysis</td><td rowspan=1 colspan=1>Less than halfthe cutoffconcentrationby GC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative (Between)50% below thecutoff and the cutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive (Betweenthe cutoff and50% above thecutoffconcentration)</td><td rowspan=1 colspan=1>High Positive(greater than50% above thecutoffconcentration)</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>BAR</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>34</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>BZO</td><td rowspan=1 colspan=1>$\ra}$</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>33</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>MDMA</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>34</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>MTD</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>80</td></tr></table>

# Co-Innovation Biotech Co.,Ltd.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>OXY</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>34</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>PCP</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>35</td><td rowspan=2 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Analysis of Discordant Results with One Step Multi-drug Test Dipcard   

<table><tr><td rowspan=1 colspan=3>One Step Multi-drug Test Dipcard</td><td rowspan=1 colspan=2>GC/MSAnalysis</td></tr><tr><td rowspan=1 colspan=1>Drug Test</td><td rowspan=1 colspan=1>Cutoff(ng/mL)</td><td rowspan=1 colspan=1>Test Result</td><td rowspan=1 colspan=1>DrugConcentration(ng/ml)</td><td rowspan=1 colspan=1>:Drug in Urine</td></tr><tr><td rowspan=1 colspan=1>BZO</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>Oxazepam</td></tr><tr><td rowspan=1 colspan=1>MDMA</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>715</td><td rowspan=1 colspan=1>3,4-Methylenedioxymethamphetamine</td></tr><tr><td rowspan=1 colspan=1>MTD</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>209</td><td rowspan=1 colspan=1>Methadone</td></tr><tr><td rowspan=1 colspan=1>PCP</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>Phencyclidine</td></tr></table>

# Other Information About Performance Characteristics:

The performance characteristics of One Step Single/Multi-drug Test Cupand One Step Single/Multi-drug Test Dipcard were evaluated by precision study, sensitivity study, specificity and cross reactivity study, interference study and stability study. The study results indicate that One Step Single/Multi-drug Test Cup and One Step Single/Multi-drug Test Dipcard perform satisfactorily when used according to the package inserts.

# 10. Conclusion:

One Step Single/Multi-drug Test Cup and One Step Single/Multi-drug Test Dipcard are substantially equivalent to UCP Home™ Drug Screening Test Cards and UCP Home™M Drug Screening Test Cup.

--- End of this section ---

Food and Drug Administration 10903 New Hampshire Avenuc Document Control Cenler  WO66-G609 Silver Spring, MD 20993-0002

June 16, 2014

CO-INNOVATION BIOTECH CO., LTD.HONG FENG, PRODUCT MANAGERNO. 13 YANYUAN ROAD. TIANHE DISTRICTGUANGZHOU, GUANGDONG 510507CH

Re: K140215 Trade/Device Name: One Step Single/Multi-drug Test Cup; One Step Single/Multi-drug Test Dipcard Regulation Number: 21 CFR 862.3150 Regulation Name: Barbiturate test system Regulatory Class: II Product Code: DIS, JXM, DJC, DJR, DJG, LCM Dated: January 28, 2014 Received: January 28, 2014

Dear Hong Feng:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassifid in accordance with the provisions of the Federal Food, Drug and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties.We remind you, however, that device labeling must be truthful and not misleading.

yur evice scassaboveintoeither lass  Specilonto)or class  A), it may be subject to additional controls. Existing major regulations affecting your device can be publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of mdical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer   
Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http:/www.fda.gov/MedicalDevices/ResourcesforYou/Industrv/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse cvents under the MDR regulation (21 CFR Part 803), please go to   
http://www.Ida.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Officc of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its tol-frec number (800) 638-2041 or (301) 796-7100 or at its Internet address htp:/www.fda.gov/MedicalDevices/RcsourcesforYou/ndustry/default.htm.

Sincerely yours.

# Courtney H. Lias -S

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

510(k) Number (if known) k140215

Device Name One Step Single/Muli-drug Test CupOne Step Single/Multi-drug Test Dp

Indications for Use (Describe)

u   oy

Test Barbiturates (BAR) Benzodiazepines (BZO) Methylenedioxymethamphetamine (MDMA) Methadone (MTD) Oxycodone (OXY) Phencyclidine (PCP)

Calibrator   
Secobarbital   
Oxazepam   
3,4-Methylenedioxymethamphetamine   
Methadone   
Oxycodone   
Phencyclidine

Cut-off level   
300 ng/mL   
300 ng/mL   
500 ng/mL   
300 ng/mL   
100 ng/mL   
25 ng/mL

in clinical laboratories only and not for point-of-care usc.

y when preliminary positive results are indicated.

# Denise Johnson-lyles -S

# FORM FDA 3881 (9/13)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.'

The burden tmeor thicolection  inoation is stated toaverage7hours pe espone, includi e tim to review instructions, search existing dat sources gather nd maintain the data needed and coplete and review the collection of information. Send comments regarding this burden estimale or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An egency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."